+关注
Tombolofish
暂无个人介绍
IP属地:未知
274
关注
9
粉丝
0
主题
0
勋章
主贴
热门
Tombolofish
2021-12-10
Hopeless in the short run
Grab shares dropped another 2% in premarket trading
Tombolofish
2021-11-26
Up
Why Are Cars.com Shares Trading Higher Today?
Tombolofish
2021-11-23
Whatever drugs the author is taking, give it to me too!
Lucid Motors Is Set Up To Surpass Tesla
Tombolofish
2021-11-22
Ok
RV Rental Company Outdoorsy Is in Talks with Rivian, Ford for EV Order
Tombolofish
2021-11-22
Fantastic
NIO shares rose more than 10% in early trading
Tombolofish
2021-11-22
$NIO Inc.(NIO)$
Keep the rise today at 10%, conserve a bit of energy and go for another burst in a few days time.. Before NIO day to reach 60 dollars
Tombolofish
2021-11-20
$Micron Technology(MU)$
Wow, what's the news for the surge up?
Tombolofish
2021-11-19
Ok
抱歉,原内容已删除
Tombolofish
2021-11-18
Fantastic
JD.com once jumped over 7% in morning trading as its Q3 revenue increased by 25.5% year-on-year
Tombolofish
2021-11-11
$Altimeter Growth Corp.(AGC)$
Probably will be a volatile counter from now till merger completed
Tombolofish
2021-11-09
$DiDi Global Inc.(DIDI)$
1
Tombolofish
2021-11-03
People buying in for the large XMAS sales period?
Tombolofish
2021-11-03
$Salesforce.com(CRM)$
Exceeding 300 dollars and still going up more
Tombolofish
2021-11-01
NIO rise is the least
EV stocks rose in Monday morning trading
Tombolofish
2021-10-28
Could a chip oversupply occur in 2 to 3 years time?
Chip Shortage Erodes Third-Quarter U.S. Economic Growth
Tombolofish
2021-10-25
Ok
Wells Fargo to roll out revamped mobile app, new virtual assistant in 2022
Tombolofish
2021-10-21
$Altimeter Growth Corp.(AGC)$
Grab has launched a Buy Now Pay Later (BNPL) service in its super app. Will this stock be valued differently?
Tombolofish
2021-10-01
$Bridgetown Holdings Limited(BTWN)$
Am still waiting
Tombolofish
2021-09-29
$Tesla Motors(TSLA)$
Head towards 1000 dollars soon
Tombolofish
2021-09-26
$Square(SQ)$
Go up to 300 dollars
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3563683901709118","uuid":"3563683901709118","gmtCreate":1600682287746,"gmtModify":1612965587786,"name":"Tombolofish","pinyin":"tombolofish","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":9,"headSize":274,"tweetSize":44,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.96%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","exceedPercentage":"80.21%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.04","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":605187945,"gmtCreate":1639130099423,"gmtModify":1639130099542,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563683901709118","idStr":"3563683901709118"},"themes":[],"htmlText":"Hopeless in the short run ","listText":"Hopeless in the short run ","text":"Hopeless in the short run","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/605187945","repostId":"1133845166","repostType":2,"repost":{"id":"1133845166","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639130022,"share":"https://www.laohu8.com/m/news/1133845166?lang=&edition=full","pubTime":"2021-12-10 17:53","market":"us","language":"en","title":"Grab shares dropped another 2% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133845166","media":"Tiger Newspress","summary":"Grab shares dropped another 2% in premarket trading.The stock fell more than 9% yesterday.","content":"<p>Grab shares dropped another 2% in premarket trading.The stock fell more than 9% yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/c53085cee57f6060446a02aa58e6a691\" tg-width=\"843\" tg-height=\"619\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grab shares dropped another 2% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrab shares dropped another 2% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-10 17:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Grab shares dropped another 2% in premarket trading.The stock fell more than 9% yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/c53085cee57f6060446a02aa58e6a691\" tg-width=\"843\" tg-height=\"619\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GRAB":"Grab Holdings"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133845166","content_text":"Grab shares dropped another 2% in premarket trading.The stock fell more than 9% yesterday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":877,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877207219,"gmtCreate":1637932350725,"gmtModify":1637932363730,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563683901709118","idStr":"3563683901709118"},"themes":[],"htmlText":"Up","listText":"Up","text":"Up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877207219","repostId":"1119733312","repostType":4,"repost":{"id":"1119733312","pubTimestamp":1637930665,"share":"https://www.laohu8.com/m/news/1119733312?lang=&edition=full","pubTime":"2021-11-26 20:44","market":"us","language":"en","title":"Why Are Cars.com Shares Trading Higher Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=1119733312","media":"Benzinga","summary":"Cars.com Inc will replace DSP Group Inc in the S&P SmallCap 600 before the opening of trading on December 2.S&P MidCap 400 constituent Synaptics Inc is acquiring DSP Group in a deal likely to be completed by December 2.Cars.com is an online destination for buying and selling new and used vehicles.Recently, Cars.com reported third-quarter FY21 revenue of $156.55 million, up 8% year-on-year, above the consensus of $156.28 million. EPS was $0.03 versus $ last year.Cars.com sees Q4 revenue of $157.5","content":"<p><b>Cars.com Inc</b> will replace <b>DSP Group Inc</b> in the S&P SmallCap 600 before the opening of trading on December 2.</p>\n<p>S&P MidCap 400 constituent <b>Synaptics Inc</b> is acquiring DSP Group in a deal likely to be completed by December 2.</p>\n<p>Cars.com is an online destination for buying and selling new and used vehicles.</p>\n<p>Recently, Cars.com reported third-quarter FY21 revenue of $156.55 million, up 8% year-on-year, above the consensus of $156.28 million. EPS was $0.03 versus $(0.18) last year.</p>\n<p>Cars.com sees Q4 revenue of $157.5 million - $159.5 million versus the consensus of $159.15 million.</p>\n<p><b>Price Action:</b> CARS shares traded higher by 7.44% at $14.30 in the premarket session on the last check Friday.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Cars.com Shares Trading Higher Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Cars.com Shares Trading Higher Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 20:44 GMT+8 <a href=https://www.benzinga.com/news/21/11/24303097/why-are-cars-com-shares-trading-higher-today><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cars.com Inc will replace DSP Group Inc in the S&P SmallCap 600 before the opening of trading on December 2.\nS&P MidCap 400 constituent Synaptics Inc is acquiring DSP Group in a deal likely to be ...</p>\n\n<a href=\"https://www.benzinga.com/news/21/11/24303097/why-are-cars-com-shares-trading-higher-today\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DSPG":"DSP Group","CARS":"Cars.com Inc."},"source_url":"https://www.benzinga.com/news/21/11/24303097/why-are-cars-com-shares-trading-higher-today","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119733312","content_text":"Cars.com Inc will replace DSP Group Inc in the S&P SmallCap 600 before the opening of trading on December 2.\nS&P MidCap 400 constituent Synaptics Inc is acquiring DSP Group in a deal likely to be completed by December 2.\nCars.com is an online destination for buying and selling new and used vehicles.\nRecently, Cars.com reported third-quarter FY21 revenue of $156.55 million, up 8% year-on-year, above the consensus of $156.28 million. EPS was $0.03 versus $(0.18) last year.\nCars.com sees Q4 revenue of $157.5 million - $159.5 million versus the consensus of $159.15 million.\nPrice Action: CARS shares traded higher by 7.44% at $14.30 in the premarket session on the last check Friday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":999,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875594593,"gmtCreate":1637666327602,"gmtModify":1637666327668,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563683901709118","idStr":"3563683901709118"},"themes":[],"htmlText":"Whatever drugs the author is taking, give it to me too! ","listText":"Whatever drugs the author is taking, give it to me too! ","text":"Whatever drugs the author is taking, give it to me too!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/875594593","repostId":"1170981862","repostType":2,"repost":{"id":"1170981862","pubTimestamp":1637656549,"share":"https://www.laohu8.com/m/news/1170981862?lang=&edition=full","pubTime":"2021-11-23 16:35","market":"us","language":"en","title":"Lucid Motors Is Set Up To Surpass Tesla","url":"https://stock-news.laohu8.com/highlight/detail?id=1170981862","media":"seekingalpha","summary":"First-movers are often assumed to carry a lasting advantage. This is not the case and, especially with the EV market, the first-mover advantage is not a powerful long-term asset.Tesla’s success has made Lucid’s challenge far more effective than it otherwise would’ve been, creating a market for the car and the investor interest required to fund the company.Lucid looks to be a far more nimble company than Tesla, allowing it to take the industry’s rapid evolution in stride, with a superior vehicle ","content":"<p>Summary</p>\n<ul>\n <li>First-movers are often assumed to carry a lasting advantage. This is not the case and, especially with the EV market, the first-mover advantage is not a powerful long-term asset.</li>\n <li>Tesla’s success has made Lucid’s challenge far more effective than it otherwise would’ve been, creating a market for the car and the investor interest required to fund the company.</li>\n <li>Lucid looks to be a far more nimble company than Tesla, allowing it to take the industry’s rapid evolution in stride, with a superior vehicle platform.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/876e502aba19c09f0db1a83835e9bcd9\" tg-width=\"768\" tg-height=\"512\" referrerpolicy=\"no-referrer\"><span>Spencer Platt/Getty Images News</span></p>\n<p>Lucid Motors (LCID) only recently began delivering its first vehicles to customers, yet it has already received the laurels of MotorTrend’s 2022 Car of the Year. The vehicle’sindustry-leading drivetrain technology, great design, and solid build quality earned it that title. Yet, Tesla (TSLA) remains the king of the EV. Of course, one car with limited volume isn’t going to change anything, though that’s not the way things are set to stay.I wrote on Lucid’s growth prospects some time ago, so that’s not the focus of today’s article. Instead, I’m here to discuss why Lucid Motors is well-positioned to surpass Tesla due to a rapidly eroding first-mover advantage. In an article on TeslaI published earlier this year, I discussed how the brand’s cache is already starting to slip. While we can sit here and debate that General Motors (GM) was actually the first EV manufacturer with its EV1 back in the ’90s, I think we all know that Tesla really earned that title. This article will discuss why that may not be such a good thing.</p>\n<p>The First-Mover Fallacy</p>\n<p>Oftentimes, the first-mover in a major new market is identified as said market’s future leader. It’s easy to see why, as they’re often associated with the market that they’ve created. Yet, think web browser and you probably think of Alphabet’s (GOOG) Google Chrome. Think of email, you’re again most likely going to think of a Google product -- this time Gmail. Social media? Facebook (FB). Cell phone? iPhone. You get the idea. What’s one thing all of these different products have in common? None of them were the first to market. Yet, despite this, they’ve all become the pinnacle of each of their respective markets.</p>\n<p>So, the big question is “Why?” Why are none of these transformative first-movers the leaders of their industry? Well, there’s not really one blanket answer.A 2005 publication to The Harvard Business Review discusses the idea of this fallacy.</p>\n<blockquote>\n “But for every academic study proving that first-mover advantages exist, there is a study proving they do not. While some well-known first-movers, such as Gillette in safety razors and Sony in personal stereos, have enjoyed considerable success, others, such as Xerox in fax machines and eToys in Internet retailing, have failed. We have found that the differences in outcome are not random—that first-mover status can confer advantages, but it does not do so categorically. Much depends on the circumstances in which it is sought.”\n</blockquote>\n<p>I find this last sentence to be particularly powerful, as every industry is vastly different and allows for alternate outcomes. There will always be some level of unpredictability, dumb luck if you will, though The Harvard Business Review identified two factors that seem to reliably indicate whether or not the first-mover advantage will last. “The pace at which the technology of the product in question is evolving and the pace at which the market for that product is expanding” are these two critical factors.</p>\n<p>The rate of innovation in the EV sector is currently one of the most impressive global efforts I’ve ever seen, as is the rate at which the market is expanding.Since 2015, global sales of EVs have grown at an average rate of 50%. Yet, this is heating up. Global EV sales in 2021are expected to rise 83% over last year, increasing the rate of adoption as more options flood the market. In order for first-movers to be successful, there needs to be substantial interest in the market. This plays into Tesla’s hands. However, the extreme level of growth in the market necessitates more competition. This opens the door for others to combat Tesla.</p>\n<p>Let’s come back to the idea of rapid innovation as well. Companies likeNano One(OTCPK:NNOMF) andSES(IVAN), both of which I’ve covered, are looking to introduce industry-shifting innovations. They’re not alone either. CATL, a Chinese battery producer, is on the verge of becoming the country’s second-largest company. CATL is on pace to spend nearly $1 billion on R&D this year, up 115% over the first half of last year. In this market of rapid innovation, it is nigh on impossible for any one company to stay at the forefront.</p>\n<p>The EV industry has failed what The Harvard Business review deemed the two most important litmus tests in determining whether a first-mover truly has any advantage. Not great news for the incumbent leader, Tesla. Though, I argue that there is more that can bring down the power of a first-mover. Complacency can create opportunities for others to thrive. In the next section, I will discuss how Tesla’s complacency, as well as a few other factors, mean that there are more reasons than a highly innovative and quickly-growing market for Tesla to fall.</p>\n<p>Where Tesla’s Faltering</p>\n<p>I think that there’s no question Lucid owes a majority of its early success to Tesla. Tesla essentially created the market for Lucid and, maybe even more importantly, got investors to pay attention to them. All of that attention allowed Lucid Motors to raise $4.4 billion in its SPAC merger with Churchill Capital. That money was enough for Lucid to bring the Air to market, continue development work on its SUV, and expand its production footprint. That’s something that Tesla never had and will be immensely powerful for Lucid Motors. Now, I’m not saying that Lucid has an easy road to mass production, far from it, but there’s no question that it’s easier than Tesla’s was. This is the first stage in which Lucid is benefiting from Tesla’s prior struggles.</p>\n<p>Though, a good start means nothing if the company can’t build on it. This is where I believe that Tesla is simply holding the door open for Lucid Motors. Tesla has seemingly become lazy and no longer has that fire to continue innovating. I can’t say I blame them, they’ve got several years on their closest competition and their cars are some of the best in the category. Well, perhaps before the Air came to market.</p>\n<p>The quality control issues that plagued Tesla in its early days were an issue, though forgivable given the company’s tumultuous path to production. Yet, there are still a number of reports concerning poor build quality. These issues are even present on the company’s $130,000 Model S Plaid. At this point, these issues are inexcusable. Especially on a $130,000 car. Lucid has worked hard to make sure it avoided making the same mistakes, even delaying initial production to do so, and it’s paid off. We’ll have to wait and see if a larger sample size produces the same result but, so far, the quality of the Air looks to be on par with its luxury price tag.</p>\n<p>The other major area that Tesla seems to be lacking in is powertrain development. Having just released a car that goes 0-60 in less than two seconds, this may seem like a bit of an unjustified claim. But that’s not the only way to measure the capability of a powertrain. In an older article, I reviewed the quality of Lucid’s core product offering. That article focused on its powertrain efficiency. The Air is capable of up to 520 miles of range, at an efficiency of 4.64 miles/kWh (the electric equivalent to miles/gallon). Granted, this is for the company’s Grand Touring trim,which costs a whopping $139,000. The base version of the Air, which costs $77,400, has an efficiency of 5.41 miles/kWh, traveling 406 miles on a single charge (using an estimated battery size of75 kWh). Tesla’s Long Range Model S, which travels412 miles on a single charge, is Tesla’s most efficient vehicle with an efficiency of 4.12 miles/kWh. I’m not going to get into the specifics on how this was achieved, as this was all explained in that previous article. For our purposes here, it’s just important to understand that it <i>was</i> done.</p>\n<p>Now, it’s easy to point to Tesla’s batteries and say that they’re the most advanced in the world. I wouldn’t argue with you there, though I’m not sure that’ll be the case for very long. It’s already becoming far less obvious than it once was, as improvements become increasingly more iterative and less significant. Essentially, Tesla’s stuck making small incremental changes while its competitors, which once were far behind, have had the chance to catch up. The company hopes that its new 4680 cells will give it the next big leap, but I think they’re moving in the wrong direction. Below is a visual representation, a top-down view of what a Tesla battery pack looks like.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dfb24c19eee013cc09407af804bcfc65\" tg-width=\"757\" tg-height=\"521\" referrerpolicy=\"no-referrer\"><span>Source: Author’s Creation</span></p>\n<p>All of the red space you see is wasted space. Trying to fit a bunch of cylinders in a rectangular container is always going to be inefficient. Hence, from a volumetric density perspective, the prismatic cell architecture is superior. In vehicles, where space is a premium, volumetric density is a critical performance benchmark. Though, I think that this speaks to a larger issue in Tesla’s battery cell development. Ina previous article, I discussed how Tesla’s batteries are becoming a liability. The company’s unwillingness to consider lithium metal batteries as the next generation of lithium-ion batteries could see the company’s battery advantage completely erode by the end of the decade.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d9f51e943a3340831639c2db1513cc4a\" tg-width=\"1280\" tg-height=\"486\" referrerpolicy=\"no-referrer\"><span>Source:C&EN</span></p>\n<p>The fact that Lucid isn’t reliant upon their own battery technology means that it is far more nimble during this time of significant battery iteration. As noted in the above section, the EV industry is likely to be driven by a series of disruptive technologies through the foreseeable future, and a company that is easily able to consistently pivot to these disruptive technologies has a better chance of staying on top of the market. To give Tesla credit, its cells are some of the best on the market. However, it’s hard to stay at the top of two different fields, car design and battery design, and the desire to do so often results in failure. The fact that Lucid walloped Tesla in drivetrain efficiency speaks to the fact that Tesla is no longer engineering the best electric vehicles and all signs point to Tesla’s battery advantage dwindling.</p>\n<p>Investor Takeaway</p>\n<p>Look, I don’t think that Tesla, or Lucid Motors for that matter, should be valued close to where they are today but the fact of the matter is that they are. If Lucid will ultimately be the stronger of the two, take that as you will. I won’t pretend that I can predict the flow of the market with companies like Tesla and Lucid, which trade so far removed from any fundamentals, but I do think that time will prove that Lucid is the better of the two companies.</p>\n<p>Ignoring share prices, Lucid Motors is gearing up for some pretty extreme growth. The company has a lot of cash on hand and is using it to invest in growing its production and product offerings. Similar to Tesla, Lucid plans to introduce mass-market vehicles after its niche offerings begin generating capital and brand awareness. As the disclosure below notes, I own shares of Lucid Motors. This may seem strange, as I just said that their fundamentals don’t come close to justifying their valuation. Though, when shares were under $20, it was far more appealing. To be completely honest, at this stage, I’m just holding to see where it goes.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lucid Motors Is Set Up To Surpass Tesla</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLucid Motors Is Set Up To Surpass Tesla\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-23 16:35 GMT+8 <a href=https://seekingalpha.com/article/4471273-lucid-motors-lcid-stock-surpass-tesla><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nFirst-movers are often assumed to carry a lasting advantage. This is not the case and, especially with the EV market, the first-mover advantage is not a powerful long-term asset.\nTesla’s ...</p>\n\n<a href=\"https://seekingalpha.com/article/4471273-lucid-motors-lcid-stock-surpass-tesla\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","LCID":"Lucid Group Inc"},"source_url":"https://seekingalpha.com/article/4471273-lucid-motors-lcid-stock-surpass-tesla","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1170981862","content_text":"Summary\n\nFirst-movers are often assumed to carry a lasting advantage. This is not the case and, especially with the EV market, the first-mover advantage is not a powerful long-term asset.\nTesla’s success has made Lucid’s challenge far more effective than it otherwise would’ve been, creating a market for the car and the investor interest required to fund the company.\nLucid looks to be a far more nimble company than Tesla, allowing it to take the industry’s rapid evolution in stride, with a superior vehicle platform.\n\nSpencer Platt/Getty Images News\nLucid Motors (LCID) only recently began delivering its first vehicles to customers, yet it has already received the laurels of MotorTrend’s 2022 Car of the Year. The vehicle’sindustry-leading drivetrain technology, great design, and solid build quality earned it that title. Yet, Tesla (TSLA) remains the king of the EV. Of course, one car with limited volume isn’t going to change anything, though that’s not the way things are set to stay.I wrote on Lucid’s growth prospects some time ago, so that’s not the focus of today’s article. Instead, I’m here to discuss why Lucid Motors is well-positioned to surpass Tesla due to a rapidly eroding first-mover advantage. In an article on TeslaI published earlier this year, I discussed how the brand’s cache is already starting to slip. While we can sit here and debate that General Motors (GM) was actually the first EV manufacturer with its EV1 back in the ’90s, I think we all know that Tesla really earned that title. This article will discuss why that may not be such a good thing.\nThe First-Mover Fallacy\nOftentimes, the first-mover in a major new market is identified as said market’s future leader. It’s easy to see why, as they’re often associated with the market that they’ve created. Yet, think web browser and you probably think of Alphabet’s (GOOG) Google Chrome. Think of email, you’re again most likely going to think of a Google product -- this time Gmail. Social media? Facebook (FB). Cell phone? iPhone. You get the idea. What’s one thing all of these different products have in common? None of them were the first to market. Yet, despite this, they’ve all become the pinnacle of each of their respective markets.\nSo, the big question is “Why?” Why are none of these transformative first-movers the leaders of their industry? Well, there’s not really one blanket answer.A 2005 publication to The Harvard Business Review discusses the idea of this fallacy.\n\n “But for every academic study proving that first-mover advantages exist, there is a study proving they do not. While some well-known first-movers, such as Gillette in safety razors and Sony in personal stereos, have enjoyed considerable success, others, such as Xerox in fax machines and eToys in Internet retailing, have failed. We have found that the differences in outcome are not random—that first-mover status can confer advantages, but it does not do so categorically. Much depends on the circumstances in which it is sought.”\n\nI find this last sentence to be particularly powerful, as every industry is vastly different and allows for alternate outcomes. There will always be some level of unpredictability, dumb luck if you will, though The Harvard Business Review identified two factors that seem to reliably indicate whether or not the first-mover advantage will last. “The pace at which the technology of the product in question is evolving and the pace at which the market for that product is expanding” are these two critical factors.\nThe rate of innovation in the EV sector is currently one of the most impressive global efforts I’ve ever seen, as is the rate at which the market is expanding.Since 2015, global sales of EVs have grown at an average rate of 50%. Yet, this is heating up. Global EV sales in 2021are expected to rise 83% over last year, increasing the rate of adoption as more options flood the market. In order for first-movers to be successful, there needs to be substantial interest in the market. This plays into Tesla’s hands. However, the extreme level of growth in the market necessitates more competition. This opens the door for others to combat Tesla.\nLet’s come back to the idea of rapid innovation as well. Companies likeNano One(OTCPK:NNOMF) andSES(IVAN), both of which I’ve covered, are looking to introduce industry-shifting innovations. They’re not alone either. CATL, a Chinese battery producer, is on the verge of becoming the country’s second-largest company. CATL is on pace to spend nearly $1 billion on R&D this year, up 115% over the first half of last year. In this market of rapid innovation, it is nigh on impossible for any one company to stay at the forefront.\nThe EV industry has failed what The Harvard Business review deemed the two most important litmus tests in determining whether a first-mover truly has any advantage. Not great news for the incumbent leader, Tesla. Though, I argue that there is more that can bring down the power of a first-mover. Complacency can create opportunities for others to thrive. In the next section, I will discuss how Tesla’s complacency, as well as a few other factors, mean that there are more reasons than a highly innovative and quickly-growing market for Tesla to fall.\nWhere Tesla’s Faltering\nI think that there’s no question Lucid owes a majority of its early success to Tesla. Tesla essentially created the market for Lucid and, maybe even more importantly, got investors to pay attention to them. All of that attention allowed Lucid Motors to raise $4.4 billion in its SPAC merger with Churchill Capital. That money was enough for Lucid to bring the Air to market, continue development work on its SUV, and expand its production footprint. That’s something that Tesla never had and will be immensely powerful for Lucid Motors. Now, I’m not saying that Lucid has an easy road to mass production, far from it, but there’s no question that it’s easier than Tesla’s was. This is the first stage in which Lucid is benefiting from Tesla’s prior struggles.\nThough, a good start means nothing if the company can’t build on it. This is where I believe that Tesla is simply holding the door open for Lucid Motors. Tesla has seemingly become lazy and no longer has that fire to continue innovating. I can’t say I blame them, they’ve got several years on their closest competition and their cars are some of the best in the category. Well, perhaps before the Air came to market.\nThe quality control issues that plagued Tesla in its early days were an issue, though forgivable given the company’s tumultuous path to production. Yet, there are still a number of reports concerning poor build quality. These issues are even present on the company’s $130,000 Model S Plaid. At this point, these issues are inexcusable. Especially on a $130,000 car. Lucid has worked hard to make sure it avoided making the same mistakes, even delaying initial production to do so, and it’s paid off. We’ll have to wait and see if a larger sample size produces the same result but, so far, the quality of the Air looks to be on par with its luxury price tag.\nThe other major area that Tesla seems to be lacking in is powertrain development. Having just released a car that goes 0-60 in less than two seconds, this may seem like a bit of an unjustified claim. But that’s not the only way to measure the capability of a powertrain. In an older article, I reviewed the quality of Lucid’s core product offering. That article focused on its powertrain efficiency. The Air is capable of up to 520 miles of range, at an efficiency of 4.64 miles/kWh (the electric equivalent to miles/gallon). Granted, this is for the company’s Grand Touring trim,which costs a whopping $139,000. The base version of the Air, which costs $77,400, has an efficiency of 5.41 miles/kWh, traveling 406 miles on a single charge (using an estimated battery size of75 kWh). Tesla’s Long Range Model S, which travels412 miles on a single charge, is Tesla’s most efficient vehicle with an efficiency of 4.12 miles/kWh. I’m not going to get into the specifics on how this was achieved, as this was all explained in that previous article. For our purposes here, it’s just important to understand that it was done.\nNow, it’s easy to point to Tesla’s batteries and say that they’re the most advanced in the world. I wouldn’t argue with you there, though I’m not sure that’ll be the case for very long. It’s already becoming far less obvious than it once was, as improvements become increasingly more iterative and less significant. Essentially, Tesla’s stuck making small incremental changes while its competitors, which once were far behind, have had the chance to catch up. The company hopes that its new 4680 cells will give it the next big leap, but I think they’re moving in the wrong direction. Below is a visual representation, a top-down view of what a Tesla battery pack looks like.\nSource: Author’s Creation\nAll of the red space you see is wasted space. Trying to fit a bunch of cylinders in a rectangular container is always going to be inefficient. Hence, from a volumetric density perspective, the prismatic cell architecture is superior. In vehicles, where space is a premium, volumetric density is a critical performance benchmark. Though, I think that this speaks to a larger issue in Tesla’s battery cell development. Ina previous article, I discussed how Tesla’s batteries are becoming a liability. The company’s unwillingness to consider lithium metal batteries as the next generation of lithium-ion batteries could see the company’s battery advantage completely erode by the end of the decade.\nSource:C&EN\nThe fact that Lucid isn’t reliant upon their own battery technology means that it is far more nimble during this time of significant battery iteration. As noted in the above section, the EV industry is likely to be driven by a series of disruptive technologies through the foreseeable future, and a company that is easily able to consistently pivot to these disruptive technologies has a better chance of staying on top of the market. To give Tesla credit, its cells are some of the best on the market. However, it’s hard to stay at the top of two different fields, car design and battery design, and the desire to do so often results in failure. The fact that Lucid walloped Tesla in drivetrain efficiency speaks to the fact that Tesla is no longer engineering the best electric vehicles and all signs point to Tesla’s battery advantage dwindling.\nInvestor Takeaway\nLook, I don’t think that Tesla, or Lucid Motors for that matter, should be valued close to where they are today but the fact of the matter is that they are. If Lucid will ultimately be the stronger of the two, take that as you will. I won’t pretend that I can predict the flow of the market with companies like Tesla and Lucid, which trade so far removed from any fundamentals, but I do think that time will prove that Lucid is the better of the two companies.\nIgnoring share prices, Lucid Motors is gearing up for some pretty extreme growth. The company has a lot of cash on hand and is using it to invest in growing its production and product offerings. Similar to Tesla, Lucid plans to introduce mass-market vehicles after its niche offerings begin generating capital and brand awareness. As the disclosure below notes, I own shares of Lucid Motors. This may seem strange, as I just said that their fundamentals don’t come close to justifying their valuation. Though, when shares were under $20, it was far more appealing. To be completely honest, at this stage, I’m just holding to see where it goes.","news_type":1},"isVote":1,"tweetType":1,"viewCount":923,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875965802,"gmtCreate":1637595073543,"gmtModify":1637595073730,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563683901709118","idStr":"3563683901709118"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875965802","repostId":"2185087223","repostType":4,"repost":{"id":"2185087223","pubTimestamp":1637593872,"share":"https://www.laohu8.com/m/news/2185087223?lang=&edition=full","pubTime":"2021-11-22 23:11","market":"us","language":"en","title":"RV Rental Company Outdoorsy Is in Talks with Rivian, Ford for EV Order","url":"https://stock-news.laohu8.com/highlight/detail?id=2185087223","media":"Bloomberg","summary":"(Bloomberg) -- Recreational vehicle rental company Outdoorsy Inc. is in talks with Rivian Automotive","content":"<p>(Bloomberg) -- Recreational vehicle rental company Outdoorsy Inc. is in talks with Rivian Automotive Inc. and Ford Motor Co. to order $100 million in electric trucks and SUVs over the coming years to build out its fleet.</p>\n<p>Outdoorsy is aiming to order roughly 1,000 Rivian trucks, Chief Executive Officer Jeff Cavins said in an interview Friday, to add to its platform for renters and employees. Cavins described the two companies’ collaboration as a “logical and organic alignment,” given Outdoorsy’s focus on nature and camping, but said delivery of the trucks wouldn’t happen until 2023 if Rivian accepted the order. Cavins later added in a statement that Outdoorsy is also talking with Ford about fulfilling part of its order.</p>\n<p>Rivian and Ford didn’t immediately respond to emailed requests for comment.</p>\n<p>Rivian, which listed on the Nasdaq earlier this month, currently has 55,400 pre-orders, the company said in regulatory filings, and is targeting production of 1,310 vehicles a week. Shares of Rivian have risen 65% since they began trading on Nov. 10</p>\n<p>Austin, Texas-based Outdoorsy was founded in 2015. It has has seen a boom in demand during the pandemic, helping it surpass $1.5 billion in total sales, Cavins said. The company had previously been in advanced talks with a special purpose acquisition company, but instead decided to seek new financing. Bloomberg reported in September that Outdoorsy hired Goldman Sachs Group Inc. to work on a filing, but Cavins said Friday no decision has been made yet on a public listing.</p>\n<p>“Last year, Outdoorsy was the only choice for travel. It was really us, and we got hit with a surge that we had a real hard time keeping up with,” he said. Demand has continued in 2021 even as air travel has rebounded, with Outdoorsy bookings up 145% year-over-year, and the company is forecasting further growth in 2022.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RV Rental Company Outdoorsy Is in Talks with Rivian, Ford for EV Order</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRV Rental Company Outdoorsy Is in Talks with Rivian, Ford for EV Order\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-22 23:11 GMT+8 <a href=https://finance.yahoo.com/news/rv-rental-company-outdoorsy-talks-135435052.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Recreational vehicle rental company Outdoorsy Inc. is in talks with Rivian Automotive Inc. and Ford Motor Co. to order $100 million in electric trucks and SUVs over the coming years to ...</p>\n\n<a href=\"https://finance.yahoo.com/news/rv-rental-company-outdoorsy-talks-135435052.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GS":"高盛","RIVN":"Rivian Automotive, Inc."},"source_url":"https://finance.yahoo.com/news/rv-rental-company-outdoorsy-talks-135435052.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2185087223","content_text":"(Bloomberg) -- Recreational vehicle rental company Outdoorsy Inc. is in talks with Rivian Automotive Inc. and Ford Motor Co. to order $100 million in electric trucks and SUVs over the coming years to build out its fleet.\nOutdoorsy is aiming to order roughly 1,000 Rivian trucks, Chief Executive Officer Jeff Cavins said in an interview Friday, to add to its platform for renters and employees. Cavins described the two companies’ collaboration as a “logical and organic alignment,” given Outdoorsy’s focus on nature and camping, but said delivery of the trucks wouldn’t happen until 2023 if Rivian accepted the order. Cavins later added in a statement that Outdoorsy is also talking with Ford about fulfilling part of its order.\nRivian and Ford didn’t immediately respond to emailed requests for comment.\nRivian, which listed on the Nasdaq earlier this month, currently has 55,400 pre-orders, the company said in regulatory filings, and is targeting production of 1,310 vehicles a week. Shares of Rivian have risen 65% since they began trading on Nov. 10\nAustin, Texas-based Outdoorsy was founded in 2015. It has has seen a boom in demand during the pandemic, helping it surpass $1.5 billion in total sales, Cavins said. The company had previously been in advanced talks with a special purpose acquisition company, but instead decided to seek new financing. Bloomberg reported in September that Outdoorsy hired Goldman Sachs Group Inc. to work on a filing, but Cavins said Friday no decision has been made yet on a public listing.\n“Last year, Outdoorsy was the only choice for travel. It was really us, and we got hit with a surge that we had a real hard time keeping up with,” he said. Demand has continued in 2021 even as air travel has rebounded, with Outdoorsy bookings up 145% year-over-year, and the company is forecasting further growth in 2022.","news_type":1},"isVote":1,"tweetType":1,"viewCount":605,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875962473,"gmtCreate":1637595051317,"gmtModify":1637595051381,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563683901709118","idStr":"3563683901709118"},"themes":[],"htmlText":"Fantastic","listText":"Fantastic","text":"Fantastic","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875962473","repostId":"1170837254","repostType":4,"repost":{"id":"1170837254","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637594462,"share":"https://www.laohu8.com/m/news/1170837254?lang=&edition=full","pubTime":"2021-11-22 23:21","market":"us","language":"en","title":"NIO shares rose more than 10% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1170837254","media":"Tiger Newspress","summary":"NIO shares rose more than 10% in early trading.Nio Inc plans to begin taking bookings for its electric sedan ET7 from mid-January onwards, cnEVportreported, citing the team working on the model.The ET7 is the fourth vehicle to go on sale from Nio’s lineup of electric vehicles.Nio launched the flagship sedan ET7 in January at the company’s annual day, complete with its second-generation electric drive system, and it is expected to compete with Tesla Inc’s Model S sedan.","content":"<p>NIO shares rose more than 10% in early trading.<img src=\"https://static.tigerbbs.com/709a7939cec9f7c36227189c8c1eb12f\" tg-width=\"871\" tg-height=\"627\" width=\"100%\" height=\"auto\"><b>Nio Inc</b> plans to begin taking bookings for its electric sedan ET7 from mid-January onwards, cnEVportreported, citing the team working on the model.</p>\n<p>The ET7 is the fourth vehicle to go on sale from Nio’s lineup of electric vehicles.</p>\n<p>Nio launched the flagship sedan ET7 in January at the company’s annual day, complete with its second-generation electric drive system, and it is expected to compete with <b>Tesla Inc’s</b> Model S sedan.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NIO shares rose more than 10% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNIO shares rose more than 10% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-22 23:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NIO shares rose more than 10% in early trading.<img src=\"https://static.tigerbbs.com/709a7939cec9f7c36227189c8c1eb12f\" tg-width=\"871\" tg-height=\"627\" width=\"100%\" height=\"auto\"><b>Nio Inc</b> plans to begin taking bookings for its electric sedan ET7 from mid-January onwards, cnEVportreported, citing the team working on the model.</p>\n<p>The ET7 is the fourth vehicle to go on sale from Nio’s lineup of electric vehicles.</p>\n<p>Nio launched the flagship sedan ET7 in January at the company’s annual day, complete with its second-generation electric drive system, and it is expected to compete with <b>Tesla Inc’s</b> Model S sedan.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170837254","content_text":"NIO shares rose more than 10% in early trading.Nio Inc plans to begin taking bookings for its electric sedan ET7 from mid-January onwards, cnEVportreported, citing the team working on the model.\nThe ET7 is the fourth vehicle to go on sale from Nio’s lineup of electric vehicles.\nNio launched the flagship sedan ET7 in January at the company’s annual day, complete with its second-generation electric drive system, and it is expected to compete with Tesla Inc’s Model S sedan.","news_type":1},"isVote":1,"tweetType":1,"viewCount":719,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875962948,"gmtCreate":1637595022269,"gmtModify":1637595022336,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563683901709118","idStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a> Keep the rise today at 10%, conserve a bit of energy and go for another burst in a few days time.. Before NIO day to reach 60 dollars","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a> Keep the rise today at 10%, conserve a bit of energy and go for another burst in a few days time.. Before NIO day to reach 60 dollars","text":"$NIO Inc.(NIO)$ Keep the rise today at 10%, conserve a bit of energy and go for another burst in a few days time.. Before NIO day to reach 60 dollars","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875962948","isVote":1,"tweetType":1,"viewCount":1388,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872997543,"gmtCreate":1637386315469,"gmtModify":1637386315645,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563683901709118","idStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MU\">$Micron Technology(MU)$</a> Wow, what's the news for the surge up? ","listText":"<a href=\"https://laohu8.com/S/MU\">$Micron Technology(MU)$</a> Wow, what's the news for the surge up? ","text":"$Micron Technology(MU)$ Wow, what's the news for the surge up?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872997543","isVote":1,"tweetType":1,"viewCount":1114,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876865443,"gmtCreate":1637292789894,"gmtModify":1637292790007,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563683901709118","idStr":"3563683901709118"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876865443","repostId":"1151370476","repostType":4,"isVote":1,"tweetType":1,"viewCount":608,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876931956,"gmtCreate":1637248129575,"gmtModify":1637248129575,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563683901709118","idStr":"3563683901709118"},"themes":[],"htmlText":"Fantastic","listText":"Fantastic","text":"Fantastic","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/876931956","repostId":"1197152718","repostType":4,"repost":{"id":"1197152718","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637247932,"share":"https://www.laohu8.com/m/news/1197152718?lang=&edition=full","pubTime":"2021-11-18 23:05","market":"us","language":"en","title":"JD.com once jumped over 7% in morning trading as its Q3 revenue increased by 25.5% year-on-year","url":"https://stock-news.laohu8.com/highlight/detail?id=1197152718","media":"Tiger Newspress","summary":"JD.com once jumped over 7% in morning trading as its Q3 revenue increased by 25.5% year-on-year.Acco","content":"<p>JD.com once jumped over 7% in morning trading as its Q3 revenue increased by 25.5% year-on-year.<img src=\"https://static.tigerbbs.com/1e91d725704486d49515aec913ec0359\" tg-width=\"770\" tg-height=\"567\" width=\"100%\" height=\"auto\">According to the financial report data, JD.com's net revenue in the third quarter was 218.7 billion yuan (about 34.3 billion US dollars), a year-on-year increase of 25.5%, exceeding the 215.61 billion yuan estimated by Bloomberg analysts.</p>\n<p>The operating profit in the third quarter was 2.6 billion yuan and the operating profit rate was 1.2%; After adjustment, the income per ADS is 3.16 yuan; Adjusted profit before interest, tax, depreciation and amortization (EBITDA) is 5.86 billion yuan, and analysts estimate 4.54 billion yuan; The adjusted operating profit margin is 2.1%, and the adjusted EBITDA profit margin is 2.7%.</p>\n<p>The net loss was 2.8 billion yuan, while the market generally expected a profit of 1.67 billion yuan.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JD.com once jumped over 7% in morning trading as its Q3 revenue increased by 25.5% year-on-year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJD.com once jumped over 7% in morning trading as its Q3 revenue increased by 25.5% year-on-year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-18 23:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>JD.com once jumped over 7% in morning trading as its Q3 revenue increased by 25.5% year-on-year.<img src=\"https://static.tigerbbs.com/1e91d725704486d49515aec913ec0359\" tg-width=\"770\" tg-height=\"567\" width=\"100%\" height=\"auto\">According to the financial report data, JD.com's net revenue in the third quarter was 218.7 billion yuan (about 34.3 billion US dollars), a year-on-year increase of 25.5%, exceeding the 215.61 billion yuan estimated by Bloomberg analysts.</p>\n<p>The operating profit in the third quarter was 2.6 billion yuan and the operating profit rate was 1.2%; After adjustment, the income per ADS is 3.16 yuan; Adjusted profit before interest, tax, depreciation and amortization (EBITDA) is 5.86 billion yuan, and analysts estimate 4.54 billion yuan; The adjusted operating profit margin is 2.1%, and the adjusted EBITDA profit margin is 2.7%.</p>\n<p>The net loss was 2.8 billion yuan, while the market generally expected a profit of 1.67 billion yuan.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JD":"京东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197152718","content_text":"JD.com once jumped over 7% in morning trading as its Q3 revenue increased by 25.5% year-on-year.According to the financial report data, JD.com's net revenue in the third quarter was 218.7 billion yuan (about 34.3 billion US dollars), a year-on-year increase of 25.5%, exceeding the 215.61 billion yuan estimated by Bloomberg analysts.\nThe operating profit in the third quarter was 2.6 billion yuan and the operating profit rate was 1.2%; After adjustment, the income per ADS is 3.16 yuan; Adjusted profit before interest, tax, depreciation and amortization (EBITDA) is 5.86 billion yuan, and analysts estimate 4.54 billion yuan; The adjusted operating profit margin is 2.1%, and the adjusted EBITDA profit margin is 2.7%.\nThe net loss was 2.8 billion yuan, while the market generally expected a profit of 1.67 billion yuan.","news_type":1},"isVote":1,"tweetType":1,"viewCount":979,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870433307,"gmtCreate":1636641438848,"gmtModify":1636641439015,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563683901709118","idStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AGC\">$Altimeter Growth Corp.(AGC)$</a> Probably will be a volatile counter from now till merger completed","listText":"<a href=\"https://laohu8.com/S/AGC\">$Altimeter Growth Corp.(AGC)$</a> Probably will be a volatile counter from now till merger completed","text":"$Altimeter Growth Corp.(AGC)$ Probably will be a volatile counter from now till merger completed","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/870433307","isVote":1,"tweetType":1,"viewCount":2098,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847918716,"gmtCreate":1636471537690,"gmtModify":1636471537815,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563683901709118","idStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/DIDI\">$DiDi Global Inc.(DIDI)$</a>1","listText":"<a href=\"https://laohu8.com/S/DIDI\">$DiDi Global Inc.(DIDI)$</a>1","text":"$DiDi Global Inc.(DIDI)$1","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/847918716","isVote":1,"tweetType":1,"viewCount":282,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848081167,"gmtCreate":1635948229310,"gmtModify":1635948229486,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563683901709118","idStr":"3563683901709118"},"themes":[],"htmlText":"People buying in for the large XMAS sales period? ","listText":"People buying in for the large XMAS sales period? ","text":"People buying in for the large XMAS sales period?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848081167","isVote":1,"tweetType":1,"viewCount":232,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848083803,"gmtCreate":1635948186708,"gmtModify":1635948186877,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563683901709118","idStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CRM\">$Salesforce.com(CRM)$</a> Exceeding 300 dollars and still going up more","listText":"<a href=\"https://laohu8.com/S/CRM\">$Salesforce.com(CRM)$</a> Exceeding 300 dollars and still going up more","text":"$Salesforce.com(CRM)$ Exceeding 300 dollars and still going up more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848083803","isVote":1,"tweetType":1,"viewCount":219,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849457154,"gmtCreate":1635775029504,"gmtModify":1635775029504,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563683901709118","idStr":"3563683901709118"},"themes":[],"htmlText":"NIO rise is the least","listText":"NIO rise is the least","text":"NIO rise is the least","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/849457154","repostId":"1133870110","repostType":4,"repost":{"id":"1133870110","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635773950,"share":"https://www.laohu8.com/m/news/1133870110?lang=&edition=full","pubTime":"2021-11-01 21:39","market":"us","language":"en","title":"EV stocks rose in Monday morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133870110","media":"Tiger Newspress","summary":"EV stocks rose in Monday morning trading.Tesla,Xpeng Motors,Li Auto,Lordstown Motors,Lucid,Nikola,Fi","content":"<p>EV stocks rose in Monday morning trading.Tesla,Xpeng Motors,Li Auto,Lordstown Motors,Lucid,Nikola,Fisker,Niu Technologies,Nikola and Faraday Future climbed between 1% and 7%.</p>\n<p><img src=\"https://static.tigerbbs.com/2f3a096b6cadbc583a7bf8a948880616\" tg-width=\"404\" tg-height=\"720\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks rose in Monday morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks rose in Monday morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-01 21:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EV stocks rose in Monday morning trading.Tesla,Xpeng Motors,Li Auto,Lordstown Motors,Lucid,Nikola,Fisker,Niu Technologies,Nikola and Faraday Future climbed between 1% and 7%.</p>\n<p><img src=\"https://static.tigerbbs.com/2f3a096b6cadbc583a7bf8a948880616\" tg-width=\"404\" tg-height=\"720\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","XPEV":"小鹏汽车","ARVN":"Arvinas Holding Company LLC","FFIE":"Faraday Future","FSR":"菲斯克","WKHS":"Workhorse Group, Inc.","NKLA":"Nikola Corporation","LCID":"Lucid Group Inc","GOEV":"Canoo Inc.","TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133870110","content_text":"EV stocks rose in Monday morning trading.Tesla,Xpeng Motors,Li Auto,Lordstown Motors,Lucid,Nikola,Fisker,Niu Technologies,Nikola and Faraday Future climbed between 1% and 7%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854868585,"gmtCreate":1635433520088,"gmtModify":1635433520277,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563683901709118","idStr":"3563683901709118"},"themes":[],"htmlText":"Could a chip oversupply occur in 2 to 3 years time? ","listText":"Could a chip oversupply occur in 2 to 3 years time? ","text":"Could a chip oversupply occur in 2 to 3 years time?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/854868585","repostId":"1115179727","repostType":4,"repost":{"id":"1115179727","pubTimestamp":1635432564,"share":"https://www.laohu8.com/m/news/1115179727?lang=&edition=full","pubTime":"2021-10-28 22:49","market":"us","language":"en","title":"Chip Shortage Erodes Third-Quarter U.S. Economic Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1115179727","media":"Bloomberg","summary":"The U.S. economy had some car troubles in the third quarter.\nPersonal consumption slowed sharply, du","content":"<p>The U.S. economy had some car troubles in the third quarter.</p>\n<p>Personal consumption slowed sharply, due in part to a drop in outlays for cars, Commerce Department data showed Thursday. That subtracted 2.39 percentage points from gross domestic product growth and drove the decline in goods spending in the period, as automakers had a tough time keeping dealer lots full.</p>\n<p>Motor vehicle production for the period dropped an annualized 41.6%, the most since a pandemic-related collapse in the second quarter of last year, the report showed. Third-quarter GDP excluding auto output rose at a 3.5% pace.</p>\n<p>Automakers are struggling to meet consumer demand as a persistent shortage of semiconductor chips stymies production. And those constraints aren’t expected to go away any time soon.</p>\n<p>“Right now, you ask us what we think the sequential increase in supply will be year-over-year, we think we’ll have about 10% more, but that’s changing weekly,” John Lawler, chief financial officer of Ford Motor Co., said of semiconductor supply during the company’s earnings call Wednesday.</p>\n<p>“But we do see that running through 2022, it could extend into 2023, although we do anticipate the scope and severity of that to reduce as we move through ‘22 into ‘23.”</p>\n<p>General Motors Co. Chief Executive Officer Mary Barra echoed the sentiment in an interview with Bloomberg Television following the company’s earnings report Wednesday.</p>\n<p>“It will linger into next year and right now our feeling is that we’ll be in much better shape in the second half of 2022,” she said.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chip Shortage Erodes Third-Quarter U.S. Economic Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChip Shortage Erodes Third-Quarter U.S. Economic Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-28 22:49 GMT+8 <a href=https://finance.yahoo.com/news/chip-shortage-erodes-third-quarter-142441713.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. economy had some car troubles in the third quarter.\nPersonal consumption slowed sharply, due in part to a drop in outlays for cars, Commerce Department data showed Thursday. That subtracted ...</p>\n\n<a href=\"https://finance.yahoo.com/news/chip-shortage-erodes-third-quarter-142441713.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GM":"通用汽车","F":"福特汽车"},"source_url":"https://finance.yahoo.com/news/chip-shortage-erodes-third-quarter-142441713.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115179727","content_text":"The U.S. economy had some car troubles in the third quarter.\nPersonal consumption slowed sharply, due in part to a drop in outlays for cars, Commerce Department data showed Thursday. That subtracted 2.39 percentage points from gross domestic product growth and drove the decline in goods spending in the period, as automakers had a tough time keeping dealer lots full.\nMotor vehicle production for the period dropped an annualized 41.6%, the most since a pandemic-related collapse in the second quarter of last year, the report showed. Third-quarter GDP excluding auto output rose at a 3.5% pace.\nAutomakers are struggling to meet consumer demand as a persistent shortage of semiconductor chips stymies production. And those constraints aren’t expected to go away any time soon.\n“Right now, you ask us what we think the sequential increase in supply will be year-over-year, we think we’ll have about 10% more, but that’s changing weekly,” John Lawler, chief financial officer of Ford Motor Co., said of semiconductor supply during the company’s earnings call Wednesday.\n“But we do see that running through 2022, it could extend into 2023, although we do anticipate the scope and severity of that to reduce as we move through ‘22 into ‘23.”\nGeneral Motors Co. Chief Executive Officer Mary Barra echoed the sentiment in an interview with Bloomberg Television following the company’s earnings report Wednesday.\n“It will linger into next year and right now our feeling is that we’ll be in much better shape in the second half of 2022,” she said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":278,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856832046,"gmtCreate":1635168306501,"gmtModify":1635168337830,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563683901709118","idStr":"3563683901709118"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856832046","repostId":"1145523290","repostType":4,"repost":{"id":"1145523290","pubTimestamp":1635167864,"share":"https://www.laohu8.com/m/news/1145523290?lang=&edition=full","pubTime":"2021-10-25 21:17","market":"us","language":"en","title":"Wells Fargo to roll out revamped mobile app, new virtual assistant in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1145523290","media":"THE BUSINESS JOURNALS","summary":"Wells Fargo & Co. (NYSE: WFC) is revamping its mobile app and adding a virtual assistant, part of th","content":"<p>Wells Fargo & Co. (NYSE: WFC) is revamping its mobile app and adding a virtual assistant, part of the company's ongoing efforts to transform its digital capabilities.</p>\n<p>The updated app will start rolling out in early 2022 to consumer, small business and wealth clients. Wells Fargo is planning an incremental rollout, with some customers seeing updates at different times. The bank wants to have the key capabilities ready first before launching other features, said Michelle Moore, head of consumer digital at Wells Fargo.</p>\n<p>Moore's team revamped the app's overall architecture and flow. It will have a clean and more functional design.</p>\n<p>\"We learned from our customers that the app was not intuitive, was not easy to use, was difficult to find things. Key things that they come into the app to do — like move money, make payments — are scattered today throughout the app,\" Moore said. \"(Customers) will see a completely new Wells Fargo app. ... Easier to use, easier to find things, easier to get to within one or two clicks at most, the ability to navigate around the app quickly.\"</p>\n<p>The revamp comes with a substantial, multiyear investment from the company, Moore said. She declined to provide more details.</p>\n<p>San Francisco-based Wells Fargo has 27 million active mobile customers. The bank tracked 1.6 billion mobile logins in the third quarter — a 14% year-over-year increase.</p>\n<p>Customers will land on an account summary page once they log in. There is a navigation bar at the bottom and an explore section to look at available products. The account details page is also redesigned for simpler access to transaction history. There is one spot for moving money, bringing together all capabilities, such as Zelle, card payments or wire transfers.</p>\n<p>Later in 2022, Wells Fargo is launching a virtual financial assistant named Fargo, accessible through the app. It is the bank's first assistant of this kind, Moore said. Fargo will be able to complete basic tasks and answer account questions. It will evolve via artificial intelligence to provide personalized insights and recommendations. Users will eventually be able to connect with bankers for additional conversations, she said, as a way to leverage in-person and digital interactions.</p>\n<p>Moore said Fargo is meant to be a value-add for customers. She said the bank's digital teams want to understand what customers are doing, what those customers need and how they want help to grow financially. The next step is engagement and learning how to fit in clients' daily lives.</p>\n<p>\"There's so much engagement to drive,\" Moore said. \"Having the foundation for a great mobile app and a great experience then lends itself to (how) we need to create awareness, adoption and focus on getting our clients to use all of the capabilities.\"</p>\n<p>Wells Fargo is also redesigning its website. Those changes will start rolling out early next year. Moore said the team is again going for a clearer, more intuitive design that offers an experience similar to the mobile app.</p>\n<p>Executives are making big changes as the bank works to reorganize operations and be more efficient. Technology is an important part of those changes. CEOCharlie Scharfhas a long to-do list in putting Wells Fargo's regulatory woes behind it, in particular shoring up risk management, rebuilding the bank's reputation and cutting costs across the lines of business. He has changed out much of the leadership team to help make it happen.</p>","source":"lsy1633760424806","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wells Fargo to roll out revamped mobile app, new virtual assistant in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWells Fargo to roll out revamped mobile app, new virtual assistant in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-25 21:17 GMT+8 <a href=https://www.bizjournals.com/charlotte/news/2021/10/25/wells-fargo-roll-out-new-mobile-app-in-2022.html?ana=yahoo><strong>THE BUSINESS JOURNALS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wells Fargo & Co. (NYSE: WFC) is revamping its mobile app and adding a virtual assistant, part of the company's ongoing efforts to transform its digital capabilities.\nThe updated app will start ...</p>\n\n<a href=\"https://www.bizjournals.com/charlotte/news/2021/10/25/wells-fargo-roll-out-new-mobile-app-in-2022.html?ana=yahoo\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WFC":"富国银行"},"source_url":"https://www.bizjournals.com/charlotte/news/2021/10/25/wells-fargo-roll-out-new-mobile-app-in-2022.html?ana=yahoo","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145523290","content_text":"Wells Fargo & Co. (NYSE: WFC) is revamping its mobile app and adding a virtual assistant, part of the company's ongoing efforts to transform its digital capabilities.\nThe updated app will start rolling out in early 2022 to consumer, small business and wealth clients. Wells Fargo is planning an incremental rollout, with some customers seeing updates at different times. The bank wants to have the key capabilities ready first before launching other features, said Michelle Moore, head of consumer digital at Wells Fargo.\nMoore's team revamped the app's overall architecture and flow. It will have a clean and more functional design.\n\"We learned from our customers that the app was not intuitive, was not easy to use, was difficult to find things. Key things that they come into the app to do — like move money, make payments — are scattered today throughout the app,\" Moore said. \"(Customers) will see a completely new Wells Fargo app. ... Easier to use, easier to find things, easier to get to within one or two clicks at most, the ability to navigate around the app quickly.\"\nThe revamp comes with a substantial, multiyear investment from the company, Moore said. She declined to provide more details.\nSan Francisco-based Wells Fargo has 27 million active mobile customers. The bank tracked 1.6 billion mobile logins in the third quarter — a 14% year-over-year increase.\nCustomers will land on an account summary page once they log in. There is a navigation bar at the bottom and an explore section to look at available products. The account details page is also redesigned for simpler access to transaction history. There is one spot for moving money, bringing together all capabilities, such as Zelle, card payments or wire transfers.\nLater in 2022, Wells Fargo is launching a virtual financial assistant named Fargo, accessible through the app. It is the bank's first assistant of this kind, Moore said. Fargo will be able to complete basic tasks and answer account questions. It will evolve via artificial intelligence to provide personalized insights and recommendations. Users will eventually be able to connect with bankers for additional conversations, she said, as a way to leverage in-person and digital interactions.\nMoore said Fargo is meant to be a value-add for customers. She said the bank's digital teams want to understand what customers are doing, what those customers need and how they want help to grow financially. The next step is engagement and learning how to fit in clients' daily lives.\n\"There's so much engagement to drive,\" Moore said. \"Having the foundation for a great mobile app and a great experience then lends itself to (how) we need to create awareness, adoption and focus on getting our clients to use all of the capabilities.\"\nWells Fargo is also redesigning its website. Those changes will start rolling out early next year. Moore said the team is again going for a clearer, more intuitive design that offers an experience similar to the mobile app.\nExecutives are making big changes as the bank works to reorganize operations and be more efficient. Technology is an important part of those changes. CEOCharlie Scharfhas a long to-do list in putting Wells Fargo's regulatory woes behind it, in particular shoring up risk management, rebuilding the bank's reputation and cutting costs across the lines of business. He has changed out much of the leadership team to help make it happen.","news_type":1},"isVote":1,"tweetType":1,"viewCount":290,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853669335,"gmtCreate":1634801686019,"gmtModify":1634801765186,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563683901709118","idStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AGC\">$Altimeter Growth Corp.(AGC)$</a> Grab has launched a Buy Now Pay Later (BNPL) service in its super app. Will this stock be valued differently? ","listText":"<a href=\"https://laohu8.com/S/AGC\">$Altimeter Growth Corp.(AGC)$</a> Grab has launched a Buy Now Pay Later (BNPL) service in its super app. Will this stock be valued differently? ","text":"$Altimeter Growth Corp.(AGC)$ Grab has launched a Buy Now Pay Later (BNPL) service in its super app. Will this stock be valued differently?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/853669335","isVote":1,"tweetType":1,"viewCount":1017,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":864071453,"gmtCreate":1633046251696,"gmtModify":1633046251862,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563683901709118","idStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BTWN\">$Bridgetown Holdings Limited(BTWN)$</a> Am still waiting","listText":"<a href=\"https://laohu8.com/S/BTWN\">$Bridgetown Holdings Limited(BTWN)$</a> Am still waiting","text":"$Bridgetown Holdings Limited(BTWN)$ Am still waiting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/864071453","isVote":1,"tweetType":1,"viewCount":354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":865064355,"gmtCreate":1632924768711,"gmtModify":1632924797896,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563683901709118","idStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a> Head towards 1000 dollars soon","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a> Head towards 1000 dollars soon","text":"$Tesla Motors(TSLA)$ Head towards 1000 dollars soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/865064355","isVote":1,"tweetType":1,"viewCount":299,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":868343388,"gmtCreate":1632614561944,"gmtModify":1632652984664,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563683901709118","idStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SQ\">$Square(SQ)$</a> Go up to 300 dollars ","listText":"<a href=\"https://laohu8.com/S/SQ\">$Square(SQ)$</a> Go up to 300 dollars ","text":"$Square(SQ)$ Go up to 300 dollars","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/868343388","isVote":1,"tweetType":1,"viewCount":131,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":118613083,"gmtCreate":1622730015942,"gmtModify":1631892984055,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BB\">$BlackBerry(BB)$</a> Buy in at too high a price 🙁","listText":"<a href=\"https://laohu8.com/S/BB\">$BlackBerry(BB)$</a> Buy in at too high a price 🙁","text":"$BlackBerry(BB)$ Buy in at too high a price 🙁","images":[{"img":"https://static.tigerbbs.com/fddcd46d3e4f422cab6078151475a8f0","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/118613083","isVote":1,"tweetType":1,"viewCount":574,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":853669335,"gmtCreate":1634801686019,"gmtModify":1634801765186,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AGC\">$Altimeter Growth Corp.(AGC)$</a> Grab has launched a Buy Now Pay Later (BNPL) service in its super app. Will this stock be valued differently? ","listText":"<a href=\"https://laohu8.com/S/AGC\">$Altimeter Growth Corp.(AGC)$</a> Grab has launched a Buy Now Pay Later (BNPL) service in its super app. Will this stock be valued differently? ","text":"$Altimeter Growth Corp.(AGC)$ Grab has launched a Buy Now Pay Later (BNPL) service in its super app. Will this stock be valued differently?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/853669335","isVote":1,"tweetType":1,"viewCount":1017,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605187945,"gmtCreate":1639130099423,"gmtModify":1639130099542,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Hopeless in the short run ","listText":"Hopeless in the short run ","text":"Hopeless in the short run","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/605187945","repostId":"1133845166","repostType":2,"isVote":1,"tweetType":1,"viewCount":877,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854868585,"gmtCreate":1635433520088,"gmtModify":1635433520277,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Could a chip oversupply occur in 2 to 3 years time? ","listText":"Could a chip oversupply occur in 2 to 3 years time? ","text":"Could a chip oversupply occur in 2 to 3 years time?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/854868585","repostId":"1115179727","repostType":4,"isVote":1,"tweetType":1,"viewCount":278,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":813557665,"gmtCreate":1630218932657,"gmtModify":1704957193684,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a> Faster back to 900","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a> Faster back to 900","text":"$Tesla Motors(TSLA)$ Faster back to 900","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/813557665","isVote":1,"tweetType":1,"viewCount":201,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818276740,"gmtCreate":1630417288380,"gmtModify":1631892984031,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/818276740","repostId":"1155360019","repostType":4,"isVote":1,"tweetType":1,"viewCount":100,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":875594593,"gmtCreate":1637666327602,"gmtModify":1637666327668,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Whatever drugs the author is taking, give it to me too! ","listText":"Whatever drugs the author is taking, give it to me too! ","text":"Whatever drugs the author is taking, give it to me too!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/875594593","repostId":"1170981862","repostType":2,"isVote":1,"tweetType":1,"viewCount":923,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876931956,"gmtCreate":1637248129575,"gmtModify":1637248129575,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Fantastic","listText":"Fantastic","text":"Fantastic","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/876931956","repostId":"1197152718","repostType":4,"isVote":1,"tweetType":1,"viewCount":979,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870433307,"gmtCreate":1636641438848,"gmtModify":1636641439015,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AGC\">$Altimeter Growth Corp.(AGC)$</a> Probably will be a volatile counter from now till merger completed","listText":"<a href=\"https://laohu8.com/S/AGC\">$Altimeter Growth Corp.(AGC)$</a> Probably will be a volatile counter from now till merger completed","text":"$Altimeter Growth Corp.(AGC)$ Probably will be a volatile counter from now till merger completed","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/870433307","isVote":1,"tweetType":1,"viewCount":2098,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":835937277,"gmtCreate":1629683696899,"gmtModify":1631888593700,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TVV.SI\">$MC Payment(TVV.SI)$</a> Is it pump and dump? ","listText":"<a href=\"https://laohu8.com/S/TVV.SI\">$MC Payment(TVV.SI)$</a> Is it pump and dump? ","text":"$MC Payment(TVV.SI)$ Is it pump and dump?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/835937277","isVote":1,"tweetType":1,"viewCount":410,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":875962948,"gmtCreate":1637595022269,"gmtModify":1637595022336,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a> Keep the rise today at 10%, conserve a bit of energy and go for another burst in a few days time.. Before NIO day to reach 60 dollars","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a> Keep the rise today at 10%, conserve a bit of energy and go for another burst in a few days time.. Before NIO day to reach 60 dollars","text":"$NIO Inc.(NIO)$ Keep the rise today at 10%, conserve a bit of energy and go for another burst in a few days time.. Before NIO day to reach 60 dollars","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875962948","isVote":1,"tweetType":1,"viewCount":1388,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":887392784,"gmtCreate":1631971325048,"gmtModify":1632805028186,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/887392784","repostId":"2168957763","repostType":4,"repost":{"id":"2168957763","pubTimestamp":1631950800,"share":"https://www.laohu8.com/m/news/2168957763?lang=&edition=full","pubTime":"2021-09-18 15:40","market":"us","language":"en","title":"FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2168957763","media":"StreetInsider","summary":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization ti","content":"<ul>\n <li><i>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants </i></li>\n <li><i>Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series</i></li>\n <li><i>Real-world data presented by Israel Ministry of Health show additional protection after receiving a</i> <i>booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine</i> <i>rollout</i></li>\n <li><i>FDA expected to make its decision in the coming days </i></li>\n</ul>\n<p><b>NEW YORK AND MAINZ, GERMANY, September 17, 2021</b>—Pfizer Inc. (NYSE: PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.</p>\n<p>VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.</p>\n<p>At this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.</p>\n<p>The FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.</p>\n<p>“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said <b>Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer</b>. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”</p>\n<p>“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said <b>Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.</b></p>\n<p>VRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.</p>\n<p>Real-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in <i>The New England Journal of Medicine</i>. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.</p>\n<p>Under the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was <u>previously authorized</u> for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.</p>\n<p>COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.</p>\n<p><b>U.S. Indication & Authorized Use</b>COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.</p>\n<ul>\n <li>It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older</li>\n <li>It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:</li>\n</ul>\n<p>The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:</p>\n<ul>\n <li>prevent COVID-19 in individuals 12 years of age and older, and</li>\n <li>provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise</li>\n</ul>\n<p>The FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.</p>\n<p><b>EUA Statement</b>This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.</p>\n<p><b>Important Safety Information</b>Individuals should <b>not</b> get the Pfizer-BioNTech COVID-19 Vaccine if they:</p>\n<ul>\n <li>had a severe allergic reaction after a previous dose of this vaccine</li>\n <li>had a severe allergic reaction to any ingredient of this vaccine</li>\n</ul>\n<p>Individuals should tell the vaccination provider about all of their medical conditions, including if they:</p>\n<ul>\n <li>have any allergies</li>\n <li>have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)</li>\n <li>have a fever</li>\n <li>have a bleeding disorder or are on a blood thinner</li>\n <li>are immunocompromised or are on a medicine that affects the immune system</li>\n <li>are pregnant, plan to become pregnant, or are breastfeeding</li>\n <li>have received another COVID-19 vaccine</li>\n <li>have ever fainted in association with an injection</li>\n</ul>\n<p>The vaccine may not protect everyone.</p>\n<p>Side effects reported with the vaccine include:</p>\n<ul>\n <li>There is a remote chance that the vaccine could cause a severe allergic reaction</li>\n <li>Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:</li>\n <li>Side effects that have been reported with the vaccine include:</li>\n <li>These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away</li>\n</ul>\n<p>There is no information on the use of the vaccine with other vaccines.</p>\n<p>Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit <u>http://www.vaers.hhs.gov</u> or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at <u>www.pfizersafetyreporting.com</u> or by calling 1-800-438-1985.</p>\n<p>Please <u>click here</u> for full Prescribing Information (16+ years of age). Please <u>click here</u> for Fact Sheet for Vaccination Providers (12+ years of age).</p>\n<p><b>About Pfizer: Breakthroughs That Change Patients’ Lives</b>At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at <u>www.Pfizer.com</u>. In addition, to learn more, please visit us on <u>www.Pfizer.com</u> and follow us on <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> at <u>@Pfizer</u> and <u>@Pfizer News</u>, <u>LinkedIn</u>, <u>YouTube</u> and like us on <a href=\"https://laohu8.com/S/FB\">Facebook</a> at <u>Facebook.com/Pfizer</u>.</p>\n<p><b>Pfizer Disclosure Notice</b>The information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p>\n<p>This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.</p>\n<p>A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at <u>www.sec.gov</u> and <u>www.pfizer.com</u>.</p>\n<p><b>About BioNTech</b>Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit <u>www.BioNTech.de</u>.</p>\n<p><b>BioNTech Forward-looking Statements</b>This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.</p>\n<p>For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at <u>www.sec.gov</u>. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 15:40 GMT+8 <a href=https://www.streetinsider.com/dr/news.php?id=18955632><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18955632\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18955632","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168957763","content_text":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series\nReal-world data presented by Israel Ministry of Health show additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout\nFDA expected to make its decision in the coming days \n\nNEW YORK AND MAINZ, GERMANY, September 17, 2021—Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.\nVRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.\nAt this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.\nThe FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.\n“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”\n“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.\nVRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.\nReal-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in The New England Journal of Medicine. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.\nUnder the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was previously authorized for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.\nCOMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.\nU.S. Indication & Authorized UseCOMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.\n\nIt is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older\nIt is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:\n\nThe Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:\n\nprevent COVID-19 in individuals 12 years of age and older, and\nprovide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise\n\nThe FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.\nEUA StatementThis emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.\nImportant Safety InformationIndividuals should not get the Pfizer-BioNTech COVID-19 Vaccine if they:\n\nhad a severe allergic reaction after a previous dose of this vaccine\nhad a severe allergic reaction to any ingredient of this vaccine\n\nIndividuals should tell the vaccination provider about all of their medical conditions, including if they:\n\nhave any allergies\nhave had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)\nhave a fever\nhave a bleeding disorder or are on a blood thinner\nare immunocompromised or are on a medicine that affects the immune system\nare pregnant, plan to become pregnant, or are breastfeeding\nhave received another COVID-19 vaccine\nhave ever fainted in association with an injection\n\nThe vaccine may not protect everyone.\nSide effects reported with the vaccine include:\n\nThere is a remote chance that the vaccine could cause a severe allergic reaction\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:\nSide effects that have been reported with the vaccine include:\nThese may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away\n\nThere is no information on the use of the vaccine with other vaccines.\nPatients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.\nPlease click here for full Prescribing Information (16+ years of age). Please click here for Fact Sheet for Vaccination Providers (12+ years of age).\nAbout Pfizer: Breakthroughs That Change Patients’ LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.\nPfizer Disclosure NoticeThe information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.\nThis release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.\nA further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.\nAbout BioNTechBiopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.\nBioNTech Forward-looking StatementsThis press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.\nFor a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.","news_type":1},"isVote":1,"tweetType":1,"viewCount":65,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":865064355,"gmtCreate":1632924768711,"gmtModify":1632924797896,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a> Head towards 1000 dollars soon","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a> Head towards 1000 dollars soon","text":"$Tesla Motors(TSLA)$ Head towards 1000 dollars soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/865064355","isVote":1,"tweetType":1,"viewCount":299,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877207219,"gmtCreate":1637932350725,"gmtModify":1637932363730,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Up","listText":"Up","text":"Up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877207219","repostId":"1119733312","repostType":4,"isVote":1,"tweetType":1,"viewCount":999,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876865443,"gmtCreate":1637292789894,"gmtModify":1637292790007,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876865443","repostId":"1151370476","repostType":4,"repost":{"id":"1151370476","pubTimestamp":1637292141,"share":"https://www.laohu8.com/m/news/1151370476?lang=&edition=full","pubTime":"2021-11-19 11:22","market":"us","language":"en","title":"Elizabeth Warren Seeks SEC Probe Into How Trump Landed SPAC Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1151370476","media":"Bloomberg","summary":"(Bloomberg) -- Donald Trump’s bid to recapture his social media presence is facing scrutiny from Sen","content":"<p>(Bloomberg) -- Donald Trump’s bid to recapture his social media presence is facing scrutiny from Senator Elizabeth Warren over reports that the blank-check company merger the former president used to raise millions of dollars may have skirted securities rules.</p>\n<p>Warren, a constant adversary of Trump’s when he occupied the White House, wants the Securities and Exchange Commission to investigate whether October’s merger between Trump Media and Technology Group and Digital World Acquisition Corp. was in the works long before the special purpose acquisition company sold shares.</p>\n<p>The Massachusetts Democrat said she’s concerned that Digital World’s chief executive officer may have held talks with Trump months ago -- discussions that weren’t disclosed to potential investors.</p>\n<p>“DWAC’s failure to disclose these talks during the process appears to be an omission of material information necessary for both early institutional investors and retail investors in the SPAC’s public offering,” she said in a Wednesday letter to SEC Chair Gary Gensler.</p>\n<p>Warren cited a New York Times report that Digital World had communicated with Trump’s firm as early as March, while stating in securities filings that the SPAC had no specific acquisition target in mind. SPACs like Digital World aren’t supposed to pursue deals until after they go public. The alleged omission enriched Digital World’s sponsors and Trump Media, while “trapping retail investors in a stock bubble,” Warren said in an accompanying statement.</p>\n<p>An SEC spokesperson declined to comment. Spokespeople for Trump Media and Digital World didn’t immediately respond to requests for comment.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elizabeth Warren Seeks SEC Probe Into How Trump Landed SPAC Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElizabeth Warren Seeks SEC Probe Into How Trump Landed SPAC Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-19 11:22 GMT+8 <a href=https://finance.yahoo.com/news/warren-seeks-sec-probe-trump-172030191.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Donald Trump’s bid to recapture his social media presence is facing scrutiny from Senator Elizabeth Warren over reports that the blank-check company merger the former president used to ...</p>\n\n<a href=\"https://finance.yahoo.com/news/warren-seeks-sec-probe-trump-172030191.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/warren-seeks-sec-probe-trump-172030191.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151370476","content_text":"(Bloomberg) -- Donald Trump’s bid to recapture his social media presence is facing scrutiny from Senator Elizabeth Warren over reports that the blank-check company merger the former president used to raise millions of dollars may have skirted securities rules.\nWarren, a constant adversary of Trump’s when he occupied the White House, wants the Securities and Exchange Commission to investigate whether October’s merger between Trump Media and Technology Group and Digital World Acquisition Corp. was in the works long before the special purpose acquisition company sold shares.\nThe Massachusetts Democrat said she’s concerned that Digital World’s chief executive officer may have held talks with Trump months ago -- discussions that weren’t disclosed to potential investors.\n“DWAC’s failure to disclose these talks during the process appears to be an omission of material information necessary for both early institutional investors and retail investors in the SPAC’s public offering,” she said in a Wednesday letter to SEC Chair Gary Gensler.\nWarren cited a New York Times report that Digital World had communicated with Trump’s firm as early as March, while stating in securities filings that the SPAC had no specific acquisition target in mind. SPACs like Digital World aren’t supposed to pursue deals until after they go public. The alleged omission enriched Digital World’s sponsors and Trump Media, while “trapping retail investors in a stock bubble,” Warren said in an accompanying statement.\nAn SEC spokesperson declined to comment. Spokespeople for Trump Media and Digital World didn’t immediately respond to requests for comment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":608,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847918716,"gmtCreate":1636471537690,"gmtModify":1636471537815,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/DIDI\">$DiDi Global Inc.(DIDI)$</a>1","listText":"<a href=\"https://laohu8.com/S/DIDI\">$DiDi Global Inc.(DIDI)$</a>1","text":"$DiDi Global Inc.(DIDI)$1","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/847918716","isVote":1,"tweetType":1,"viewCount":282,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849457154,"gmtCreate":1635775029504,"gmtModify":1635775029504,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"NIO rise is the least","listText":"NIO rise is the least","text":"NIO rise is the least","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/849457154","repostId":"1133870110","repostType":4,"isVote":1,"tweetType":1,"viewCount":176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":864071453,"gmtCreate":1633046251696,"gmtModify":1633046251862,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BTWN\">$Bridgetown Holdings Limited(BTWN)$</a> Am still waiting","listText":"<a href=\"https://laohu8.com/S/BTWN\">$Bridgetown Holdings Limited(BTWN)$</a> Am still waiting","text":"$Bridgetown Holdings Limited(BTWN)$ Am still waiting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/864071453","isVote":1,"tweetType":1,"viewCount":354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":869300506,"gmtCreate":1632239865505,"gmtModify":1632801822309,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a> up and up ","listText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a> up and up ","text":"$Sea Ltd(SE)$ up and up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/869300506","isVote":1,"tweetType":1,"viewCount":55,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885540723,"gmtCreate":1631805433862,"gmtModify":1631883804954,"author":{"id":"3563683901709118","authorId":"3563683901709118","name":"Tombolofish","avatar":"https://static.tigerbbs.com/3ed36505d552a33ebb89f966837d2260","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563683901709118","authorIdStr":"3563683901709118"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a> Go up more","listText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a> Go up more","text":"$Palantir Technologies Inc.(PLTR)$ Go up more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/885540723","isVote":1,"tweetType":1,"viewCount":6,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}